CO-OPTIV-SECURITY
30.5.2019 17:07:07 CEST | Business Wire | Press release
Optiv Security, a global cybersecurity integrator delivering end-to-end cybersecurity solutions, has been recognized with the second highest score in the current offering category for cybersecurity incident response services by Forrester Research. The Forrester WaveTM : Cybersecurity Incident Response Services, Q1 2019 identifies Optiv as having received the highest possible score for the criteria of incident preparation, post-incident reporting and support, and average hours per response.
The report cites that “Optiv … has an excellent current offering,” noting that “it has a well-stated engagement model, and its postmortem deliverables include remediation road maps to help clients avoid repeat occurrences, and its client references were positive across the board.” The report also states that “Optiv would be a good choice from incident preparation through remediation.”
“Today’s business decision makers are faced with driving technology, product, and business growth, while being simultaneously tasked with maintaining cyber resilient programs that are ready to react, respond to, and recover from adverse events,” said Bill Young, Optiv’s vice president and general manager of advisory threat management. “Achieving cyber resiliency requires a strategy that leverages security best practices, including proactive incident management planning, programmatic penetration testing, effective detection and response capabilities, and real-time tailored threat intelligence. By addressing enterprise cybersecurity needs from the perspective of the enemy, organizations can create more successful cyber resilient programs that are built on factual-based offensive security testing.”
Young continued, “Optiv is in a unique position in the industry to provide clients with unmatched insight, depth and breadth of services, as well as a bench that extends throughout the complete ‘plan, build, run’ cybersecurity lifecycle. We are focused on enabling our clients to move from putting out fires to preventing threat actor actions and enabling their businesses. We do this by helping organizations create, prepare, and execute incident response strategies that are honed and practiced as their organizations change, providing skilled and experienced resources to augment internal staff, and delivering supporting services, such as threat hunting and forensics capabilities that help reduce breach levels and data loss. We believe receiving the second highest score in the current offering category from Forrester validates our unique approach and the positive impact we have on our clients’ operations.”
Optiv’s enterprise incident management services help organizations reduce the likelihood of attacks or incidents, secure their environments against threats, and recover from incidents while minimizing disruption. Optiv’s full suite of EIM services can be purchased in structures aligned to the clients’ business model, thereby enabling organizations to:
- Prepare – identify gaps in incident management strategy, hunt for and detect unknown threats within their infrastructure, document key personnel and escalation steps, validate and test response efforts for incidents and identify next steps to become more resilient.
- Respond During and Post Incident – uncover attackers’ actions, detail the scope of a compromise, identify steps to remove active threats found in their environments, limit data loss, and improve security controls.
- Maintain – ensure they are in a continual state of readiness for unexpected attacks or incidents with Optiv experts who are on-call and available 24x7x365. Optiv’s security and malware professionals examine clients’ systems for indicators of compromise, conduct analysis informed by a vast proprietary knowledge store of malicious code, signatures and attacks, and provide ongoing expertise.
Please visit Optiv’s website to learn more about Optiv’s incident management services .
Follow Optiv
Twitter: www.twitter.com/optiv
LinkedIn:
www.linkedin.com/company/optiv-inc
Facebook:
www.facebook.com/optivinc
YouTube:
https://www.youtube.com/c/OptivInc
Blog:
www.optiv.com/explore-optiv-insights/blog
About Optiv Security
Optiv is a global cybersecurity
solutions integrator – a “one-stop” trusted partner with a singular
focus on cybersecurity. Our end-to-end cybersecurity capabilities span
risk management and transformation, cyber digital transformation, threat
management, cyber operations, identity and data management, and
integration and innovation, helping organizations realize stronger,
simpler and more cost-efficient cybersecurity programs that support
business requirements and outcomes. At Optiv, we are modernizing
cybersecurity to enable clients to innovate their consumption models,
integrate infrastructure and technology to maximize value, achieve
measurable outcomes, and realize complete solutions and business
alignment. For more information about Optiv, please visit us at www.optiv.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190530005565/en/
Contact:
Jason Cook (816) 701-3374 Jason.cook@optiv.com or Brett Ater (913) 304-7683 Brett.ater@optiv.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
